Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia

Drugs of Today

Volumn 46, Issue 7, 2010, Pages 463-471

  Owen, R T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PALIPERIDONE; RISPERIDONE; SUSTENNA; UNCLASSIFIED DRUG;

AKATHISIA; ANXIETY; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; LOW DRUG DOSE; PARKINSONISM; PSYCHOSIS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE;

ANTIPSYCHOTIC AGENTS; DOSAGE FORMS; DRUG STORAGE; EVIDENCE-BASED MEDICINE; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; PALMITATES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 77958164916     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.7.1514647     Document Type: Review

References (21)

1. Owen, R.T. Extended-release paliperidone: Efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today 2007, 43(4): 249-58.
2. Nasrallah, H. The case for long-acting antipsychotics in the post CATIE era. Acta Psychiatr Scand 2007, 115(4): 260-67. (Pubitemid 46425751)
3. Owen, R.T. Olanzapine: A review of rapid and long-acting parenteral formulations. Drugs Today 2010, 46(3): 173-81.
4. Chue, P. Long acting risperidone injection, efficacy, safety and cost effectiveness of the first long acting atypical antipsychotic. Neuropsychiatr Dis Treatment 2007, 3(1): 13-39.
5. Invega® Sustenna® US Prescribing Information. www.invegasustenna.com/shared/pi/invegasustenna.pdf (Accessed 1 June 2010).
6. Kern-Sliwa, J., Samtani, M.N., Haskins, J.J. et al. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: Pharmacokinetic rationale based on modelling and simulation. Annu Meet Coll Psychiatric Neurologic Pharmacists (April 19-22, Jacksonsille, FL) 2009, Abst NR1-046.
7. Kapur, S., Zipursky, R.B., Remington, G. Clinical and theoretical implications of 5HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am J Psychiatry 1999, 156(2): 268-93.
8. Cleton, A., Rossenu, S., Hough, D. et al. Assessment of the dose-proportionality of paliperidone palmitate 25, 50, 100 and 150 mg eq: A new long-acting injectable antipsychotic following administration into the deltoid or gluteal muscles. Clin Pharmacol Ther 2008, 83(Suppl. 1): Abst PI-74 [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (April 2-5, Orlando) 2008].
9. Samtani, M.N., Vermulen, A., Stuyckens, K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: A novel once monthly long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 2009, 48(9): 585-600.
10. Gopal, S., Hough, D.W., Xu, H. et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: A randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010. April 2010. Epub ahead of print.
11. Kramer, M., Litman, R., Hough, D. et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia: Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010, 13(5): 635-647.
12. Nasrallah, H., Gopal, S., Kern-Sliwa, J. et al. Efficacy and safety of three doses of paliperidone palmiate, an investigational long-acting injectable antipsychotic in schizophrenia. 161st Annu Meet Am Psychiatr Assoc (May 3-8, Washington DC) 2008, Abst NR4-036.
13. Pandina, G.J., Lindenmayer, J-P., Lull, J. et al. A randomized, placebo-controlled study to assess the efficacy and safety of three doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010, 30(6): 235-44.
14. Hough, D., Gopal, S., Vijapurkar, U. et al. Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schiz Res 2010, 116(2-3): 107-17.
15. Alphs, L., Bossie, C., Kern-Sliwa, J. et al. Paliperidone palmitate: Clinical response in subjects with schizophrenia with recent versus longer-term duration of illness. 162nd Annu Meet Am Psychiatr Assoc (May 16-21, San Francisco) 2009, Abst NR6-027.
16. Gopal, S., Vijapurkar, U., Lim, P. et al. Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia. 162nd Annu Meet Am Psychiatr Assoc (May 16-21, San Francisco) 2009, Abst NR1-031.
17. Coppola, D., Liu, Y., Gopal, S. et al. Long-term safety, tolerability and pharmacokinetics of paliperidone palmitate 234 mg (150 mg eq), the highest marketed dose: A 1-year open-label study in patients with schizophrenia. Am Meet Soc Clin Pharmacol Ther (March 17-20, Altlanta, GA) 2010. Abst PI-49.
18. Nicholl, D., Nasrallah, H., Nuamah, I., Akhras, K., Gagnon,D.D., Gopal, S. Personal and social functioning in schizophrenia: Defining a clinically meaningful measure of maintenance in relapse prevention. Curr Med Res Opin 2010, 26(6): 1471-84.
19. Fleischhakker, W.W., Gopal, S., Samtani, M.N. et al. Optimization of the dosing strategy for the long acting injectable antipsychotic paliperidone palmitate: Results of two randomized, double-blind studies and population pharmacokinetic simulations. 47th Annu Meet Am Coll Neuropsychopharmacol (December 7-11, Scottsdale, AZ) 2008, Poster presentation.
20. Pandina, G., Lane, R., Gopal, S., Gassman-Mayer, C., Hough, D., Remmerie, B., Simpson, G. A randomized, double-blind comparative study of flexible doses of paliperdone palmitate and risperidone long-acting therapy in patients with schizophrenia. 48th Ann Meet Am Coll Neuropsychopharmacol (December 6-10, Florida, MI) 2009, Abst 202.
21. Hough, D., Lindenmayer, J-P., Gopal, S. et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33: 1022-31.